Hemophilic Arthropathy in Children: Impact of Inhibitors on Musculoskeletal Outcomes and Disease Progression

Mervat ATfy Mohammed [1], Hossam Mostafa Kamal [2], Mohamed Atia Mortada [3], Moursy Mabrouk Abdallah Attia Moursy [4]

1 Professor of Pediatrics, Faculty of Medicine, Zagazig University
2 Professor of Pediatrics, Faculty of Medicine, Zagazig University
3 Professor of Rheumatology, Faculty of Medicine, Zagazig University
4 Assistant Fellow in pediatric intensive care unit ALAHRAR teaching hospital

Corresponding Author: Moursy Mabrouk Abdallah Attia Moursy

Received: 28 October 2024, **Accepted:** 17 November 2024, **Published:** 20 November 2024

Abstract

Background: Hemophilia is a hereditary X-linked bleeding disorder characterized by deficiency of coagulation factors VIII or IX, leading to recurrent bleeding episodes, particularly within joints and muscles. In pediatric patients, repeated hemarthroses represent the most significant clinical manifestation, initiating a cascade of pathological events that culminate in hemophilic arthropathy. This chronic musculoskeletal complication is a major source of morbidity, resulting in progressive joint destruction, pain, functional impairment, and reduced quality of life. Despite advances in prophylactic therapies, musculoskeletal complications remain prevalent, particularly in children with severe disease phenotypes.

The development of inhibitors—neutralizing antibodies against replacement clotting factors—has emerged as one of the most challenging complications in hemophilia management. Inhibitors compromise the efficacy of standard replacement therapy, leading to poorly controlled bleeding episodes and increased frequency of hemarthrosis. Consequently, children with inhibitors are at a significantly higher risk of accelerated joint damage and early onset of arthropathy. The interaction between inhibitor status and musculoskeletal outcomes is complex, involving increased inflammatory responses, persistent synovitis, and impaired hemostatic control, all of which contribute to disease progression.

The pathophysiology of hemophilic arthropathy involves recurrent intra-articular bleeding, iron deposition, synovial hypertrophy, and chronic inflammation, ultimately resulting in cartilage degradation and osteochondral damage. These processes are particularly detrimental in children, as growing joints are more susceptible to irreversible structural changes. Additionally, various genetic, environmental, and treatment-related factors—including timing of prophylaxis, treatment adherence, and physical activity—modulate disease severity and progression.

This review aims to provide a comprehensive overview of hemophilic arthropathy in pediatric patients, with a particular focus on the impact of inhibitors on musculoskeletal outcomes and disease progression. It explores the underlying mechanisms, clinical manifestations, and contributing risk factors, while highlighting the critical importance of early diagnosis, individualized management strategies, and emerging therapeutic approaches. Understanding the interplay between inhibitors and joint disease is essential for optimizing long-term musculoskeletal health and improving functional outcomes in children with hemophilia.

Keywords: *Hemophilia; Pediatric hemophilia; Hemophilic arthropathy; Musculoskeletal assessment; Hemarthrosis; Hemophilia Joint Health Score (HJHS); Ultrasound; Magnetic resonance imaging; Joint evaluation; Early detection*

Introduction

Hemophilia is a congenital X-linked bleeding disorder resulting from deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), leading to impaired thrombin generation and ineffective clot formation. It predominantly affects males, although females may present as symptomatic carriers. The severity of the disease is determined by the residual clotting factor level, with severe hemophilia (<1% activity) being associated with frequent spontaneous bleeding episodes, particularly into joints and muscles. These recurrent bleeding events represent the hallmark of the disease and are the primary drivers of long-term morbidity in pediatric patients [1].

In children with hemophilia, musculoskeletal bleeding—especially hemarthrosis—is the most common clinical manifestation and typically begins early in life, often around the time of ambulation. Repeated joint bleeding initiates a progressive pathological process characterized by synovial inflammation, hypertrophy, and recurrent hemorrhage, eventually leading to chronic hemophilic arthropathy. Target joints, defined by recurrent bleeding episodes, commonly involve the knees, ankles, and elbows, and are associated with pain, reduced range of motion, and functional disability. Without adequate prevention and management, these changes can begin in early childhood and progress rapidly, significantly impairing physical development and quality of life [2].

The pathogenesis of hemophilic arthropathy is multifactorial and involves a complex interplay between mechanical, inflammatory, and biochemical processes. Following intra-articular bleeding, blood degradation products—particularly iron—accumulate within the synovium, triggering chronic inflammation and promoting synovial proliferation. This hypertrophic synovium becomes highly vascularized and fragile, predisposing to further bleeding and establishing a vicious cycle of joint damage. Over time, inflammatory mediators and oxidative stress contribute to cartilage degradation and subchondral bone changes, ultimately resulting in irreversible joint destruction [3].

Despite significant advances in hemophilia care, including the widespread use of prophylactic clotting factor replacement, musculoskeletal complications remain a major clinical concern. One of the most critical challenges in modern hemophilia management is the development of inhibitors—neutralizing alloantibodies directed against infused clotting factors. These inhibitors render standard replacement therapy ineffective, leading to inadequate control of bleeding episodes. As a result, children with inhibitors experience more frequent and severe hemarthroses, which accelerates joint deterioration and increases the risk of early-onset arthropathy [4].

The incidence of inhibitor development is particularly high in patients with severe hemophilia A, affecting up to 30% of this population, while it is less common in hemophilia B. The presence of inhibitors not only complicates treatment strategies but also imposes a significant burden in terms of healthcare costs, treatment complexity, and patient outcomes. Bypassing agents and immune tolerance induction have improved management; however, their variable efficacy and associated challenges mean that joint bleeding is often not optimally controlled in these patients [5].

In pediatric populations, the impact of inhibitors extends beyond increased bleeding frequency to include alterations in the inflammatory milieu of the joint, potentially exacerbating synovial pathology and joint damage. Moreover, the early onset of joint disease in children with inhibitors interferes with normal growth, physical activity, and psychosocial development. This underscores the importance of early identification of high-risk patients and implementation of tailored therapeutic strategies aimed at preserving joint health [6].

Although numerous studies have explored hemophilic arthropathy and its clinical consequences, there remains a significant gap in understanding the precise relationship between inhibitor development and musculoskeletal outcomes in children. Most available data focus either on general joint disease progression or on inhibitor epidemiology, with limited integration of both aspects in a pediatric context. Additionally, variability in assessment tools and outcome measures further complicates the evaluation of disease burden and progression [7].

Therefore, this review aims to comprehensively examine hemophilic arthropathy in pediatric patients,

with a particular emphasis on the impact of inhibitors on musculoskeletal outcomes and disease progression. It seeks to integrate current knowledge on pathophysiology, clinical manifestations, and contributing risk factors, while highlighting the unique challenges posed by inhibitors. Addressing this knowledge gap is essential for improving early intervention strategies, optimizing individualized care, and ultimately enhancing long-term functional outcomes and quality of life in children with hemophilia [8].

Pathophysiology of Hemophilic Arthropathy in Children

Hemophilic arthropathy represents the end result of a complex and progressive pathological process initiated by recurrent hemarthrosis, which begins early in life in children with moderate to severe hemophilia. The deficiency of coagulation factors VIII or IX impairs the formation of the tenase complex, leading to inadequate thrombin generation and ineffective clot stabilization. Consequently, even minor trauma or spontaneous vascular injury within the joint space can result in prolonged bleeding. The synovial joints, particularly those subjected to mechanical stress such as the knees, ankles, and elbows, are especially vulnerable to repeated hemorrhagic episodes, establishing the foundation for chronic joint disease [9].

The earliest pathological event in hemophilic arthropathy is intra-articular bleeding, which introduces blood components into the joint cavity. Normally, a single joint bleed may be cleared efficiently; however, in hemophilia, recurrent bleeding overwhelms the synovial clearance mechanisms. Blood breakdown products, particularly iron in the form of hemosiderin, accumulate within synovial macrophages. This iron deposition is a key driver of synovial inflammation, promoting oxidative stress and triggering the release of pro-inflammatory cytokines. Over time, this results in persistent synovitis characterized by synovial hypertrophy and hyperplasia [10].

Synovial inflammation plays a central role in perpetuating joint damage. The inflamed synovium becomes highly vascularized due to neoangiogenesis, driven by factors such as vascular endothelial growth factor (VEGF). These newly formed blood vessels are structurally fragile and prone to rupture, thereby increasing the likelihood of recurrent bleeding even in the absence of significant trauma. This creates a vicious cycle in which bleeding leads to inflammation, and inflammation predisposes to further bleeding. The chronicity of this process is particularly detrimental in children, whose joints are still developing and are more susceptible to structural alterations [11].

At the cellular level, macrophages within the synovium exhibit distinct phenotypic changes in response to repeated bleeding. Initially, a pro-inflammatory (M1) macrophage response predominates, characterized by the release of cytokines such as tumor necrosis factor-alpha, interleukin-1β, and interleukin-6. These mediators contribute to cartilage degradation by stimulating chondrocytes to produce catabolic enzymes and reactive oxygen species. Subsequently, a shift toward an anti-inflammatory (M2) macrophage phenotype occurs, which promotes tissue remodeling and angiogenesis but may also contribute to abnormal synovial proliferation and fibrosis. This imbalance between inflammatory and reparative processes further accelerates joint deterioration [12].

Cartilage damage is another critical component of hemophilic arthropathy and can occur early in the disease course. Blood exposure within the joint is directly toxic to cartilage, with studies demonstrating that even short-term exposure to blood can induce chondrocyte apoptosis and impair matrix synthesis. Iron-mediated oxidative stress and the formation of hydroxyl radicals exacerbate this damage, leading to progressive loss of cartilage integrity. In pediatric patients, the vulnerability of growing cartilage further amplifies the impact of these pathological processes, resulting in earlier and more severe joint degeneration compared to adults [13].

In addition to cartilage destruction, subchondral bone changes play a significant role in disease progression. Chronic inflammation and altered joint biomechanics disrupt the balance between bone formation and resorption, primarily through dysregulation of the RANK/RANKL/osteoprotegerin pathway. This leads to increased osteoclastic activity and subchondral bone loss, followed by the formation of cysts, erosions, and joint deformities in advanced stages. These structural changes contribute to pain, stiffness, and reduced joint function, further impairing mobility and quality of life

[14].

The presence of inhibitors significantly exacerbates the pathophysiological cascade of hemophilic arthropathy. Inhibitors neutralize infused clotting factors, resulting in suboptimal hemostatic control and increased frequency of bleeding episodes. Consequently, patients with inhibitors experience more persistent synovitis and accelerated joint damage. Additionally, the immune response associated with inhibitor development may alter the intra-articular inflammatory environment, further promoting synovial proliferation and tissue destruction. This highlights the critical role of inhibitors as a modifier of disease severity and progression [15].

Overall, hemophilic arthropathy in children is the result of a self-perpetuating cycle involving recurrent bleeding, chronic inflammation, and progressive structural joint damage. The interplay between synovitis and osteochondral destruction underscores the importance of early intervention to interrupt this cycle. Understanding these mechanisms provides a foundation for developing targeted therapeutic strategies aimed at preserving joint integrity and improving long-term musculoskeletal outcomes in pediatric patients with hemophilia, particularly those complicated by inhibitor development [16].

Clinical Manifestations of Musculoskeletal Involvement in Pediatric Hemophilia

Musculoskeletal bleeding represents the hallmark clinical feature of hemophilia in children and is the primary determinant of long-term morbidity. The pattern and severity of bleeding vary with age, disease severity, and treatment adequacy. While neonates may present with soft tissue or intracranial bleeding, joint bleeding becomes increasingly prominent as children begin to crawl and walk. Hemarthrosis typically emerges in early childhood and progresses in frequency and severity in patients with severe hemophilia, particularly in the absence of effective prophylaxis. These recurrent bleeding episodes initiate a cascade of joint damage that defines the clinical course of hemophilic arthropathy [17].

Hemarthrosis most commonly affects large synovial joints, particularly the knees, ankles, and elbows, which account for approximately 80% of joint bleeds. The initial episodes may present with subtle symptoms such as tingling or discomfort, followed by pain, swelling, warmth, and reduced range of motion. In young children, irritability and refusal to bear weight may be early indicators. If not promptly treated, repeated bleeding leads to the development of “target joints,” defined as joints experiencing recurrent hemorrhage over a short period. These joints become the epicenter of progressive structural damage and functional decline [18].

With repeated hemarthroses, chronic synovitis develops, characterized by persistent joint swelling and hypertrophy of the synovial membrane. Clinically, this manifests as joint stiffness, decreased mobility, and recurrent pain, even in the absence of acute bleeding. Over time, the joint undergoes structural remodeling, including cartilage degradation and bone changes, leading to deformities such as flexion contractures and joint instability. In pediatric patients, these changes can significantly impair normal growth and development, affecting gait patterns and physical activity levels [19].

Pain is a central feature of hemophilic arthropathy and may be acute, associated with active bleeding, or chronic due to established joint damage. Chronic pain often leads to reduced physical activity, muscle weakness, and further joint instability, creating a cycle of deterioration. Children may adapt their movements to minimize discomfort, resulting in abnormal biomechanics that exacerbate joint stress and accelerate degeneration. This functional limitation can extend beyond physical health, impacting psychosocial well-being and participation in daily activities [20].

Muscle hemorrhages represent another important component of musculoskeletal involvement, accounting for a significant proportion of bleeding episodes. These are often associated with trauma or invasive procedures and commonly affect muscles such as the iliopsoas, quadriceps, and calf muscles. Clinically, muscle bleeds may present with localized pain, swelling, and limited movement. Severe cases can lead to complications such as compartment syndrome, nerve compression, and muscle contractures, which further contribute to long-term disability if not adequately managed [21].

The presence of inhibitors significantly alters the clinical presentation and severity of musculoskeletal manifestations. Children with inhibitors experience more frequent and less controllable bleeding episodes due to the reduced efficacy of standard replacement therapy. As a result, hemarthroses tend to

be more severe, prolonged, and recurrent, accelerating the progression to chronic arthropathy. Additionally, these patients often require alternative treatments such as bypassing agents, which may not provide the same level of bleed prevention, further increasing the risk of joint deterioration [22].

Functional impairment becomes increasingly evident as joint damage progresses. Limitations in range of motion, muscle atrophy, and joint deformities collectively impair mobility and independence. These changes are often measurable by school age in children with severe disease and may progress into adolescence if not adequately addressed. Importantly, studies have shown that joint range of motion limitations can occur even in patients with fewer clinically apparent bleeding episodes, suggesting the presence of subclinical joint damage [23].

Overall, the clinical manifestations of musculoskeletal involvement in pediatric hemophilia reflect a continuum from acute bleeding episodes to chronic joint disease and disability. The severity and progression of these manifestations are strongly influenced by the presence of inhibitors, timing of treatment initiation, and adequacy of prophylaxis. Early recognition and comprehensive management are essential to prevent irreversible joint damage and to preserve functional outcomes in this vulnerable population [24].

Role of Inhibitors in Disease Progression and Musculoskeletal Outcomes

The development of inhibitors represents one of the most significant complications in the management of pediatric hemophilia and has profound implications for musculoskeletal health. Inhibitors are neutralizing alloantibodies directed against infused clotting factors, most commonly factor VIII, and less frequently factor IX. Their presence renders standard replacement therapy ineffective by reducing factor recovery and shortening its half-life. Consequently, achieving adequate hemostasis becomes challenging, leading to increased frequency, severity, and duration of bleeding episodes, particularly within joints [25].

In pediatric patients, inhibitors typically develop early in the course of treatment, most commonly within the first 50 exposure days to clotting factor concentrates. The incidence is highest among children with severe hemophilia A, affecting approximately 20–30% of patients, while it remains significantly lower in hemophilia B. The early onset of inhibitors is particularly concerning because it coincides with a critical period of musculoskeletal development, during which joints are highly susceptible to damage. This temporal relationship contributes to the early establishment of joint disease in affected children [26].

The presence of inhibitors fundamentally alters the natural history of hemophilia by exacerbating bleeding tendencies. Inhibitor-positive patients experience more frequent hemarthroses, which are often more difficult to control and may persist longer than in patients without inhibitors. This results in prolonged exposure of joint tissues to blood, intensifying synovial inflammation and accelerating the pathological processes underlying hemophilic arthropathy. The inability to effectively prevent or rapidly control joint bleeds places these patients at a significantly higher risk of developing target joints and chronic joint disease [27].

From a pathophysiological perspective, inhibitors may also influence the intra-articular environment beyond their effect on hemostasis. The immune response associated with inhibitor formation involves activation of T cells and B cells, leading to the production of pro-inflammatory cytokines. This heightened immune activity may amplify synovial inflammation and contribute to a more aggressive form of arthropathy. Additionally, persistent immune activation may interfere with normal tissue repair mechanisms, further promoting joint deterioration [28].

Management of patients with inhibitors requires the use of alternative therapeutic strategies, including bypassing agents such as activated prothrombin complex concentrates and recombinant activated factor VII. While these agents can achieve hemostasis, their efficacy is variable and less predictable compared to standard factor replacement therapy. This unpredictability may result in suboptimal bleed control, allowing continued joint damage. Furthermore, the lack of reliable laboratory monitoring tools for these agents complicates dose optimization and clinical decision-making [29].

Immune tolerance induction (ITI) remains the only established strategy for eradicating inhibitors, aiming

to restore responsiveness to factor replacement therapy. Although ITI is successful in a significant proportion of patients with hemophilia A, it is resource-intensive, requires prolonged treatment durations, and is not universally effective. During the period of ITI, patients remain vulnerable to bleeding complications, which can further compromise joint health. Additionally, ITI is less successful in hemophilia B and may be associated with severe adverse reactions, limiting its applicability in this subgroup [30].

The introduction of non-factor therapies, such as emicizumab, has transformed the management landscape for patients with inhibitors. By mimicking the function of factor VIII and providing more stable hemostatic coverage, these agents have demonstrated significant reductions in bleeding rates. Early evidence suggests that improved bleed control with such therapies may help preserve joint health and reduce the progression of arthropathy. However, long-term data on musculoskeletal outcomes, particularly in pediatric populations, are still emerging and require further investigation [31].

Overall, inhibitors serve as a critical modifier of disease severity in pediatric hemophilia, with a substantial impact on musculoskeletal outcomes. Their presence not only increases bleeding frequency but also accelerates joint damage through both mechanical and immunological mechanisms. Addressing inhibitor development through preventive strategies, early detection, and optimized management is essential to mitigate their detrimental effects and improve long-term joint health in children with hemophilia [32].

Determinants and Risk Factors of Hemophilic Arthropathy Progression in Children

1. Disease Severity and Baseline Factor Levels

The severity of hemophilia, defined by residual plasma levels of factor VIII or IX, remains the most fundamental determinant of musculoskeletal outcomes. Children with severe hemophilia (<1% activity) exhibit spontaneous and recurrent hemarthroses beginning early in life, often coinciding with the onset of ambulation. This early exposure of joints to repeated bleeding establishes the foundation for progressive arthropathy. However, clinical heterogeneity exists, as patients with similar factor levels may demonstrate markedly different joint outcomes, indicating that factor deficiency alone is insufficient to fully predict disease progression [33].

2. Recurrent Hemarthrosis and Target Joint Formation

Recurrent joint bleeding is the central pathogenic driver of hemophilic arthropathy. The concept of the "target joint," defined as a joint experiencing ≥4 bleeding episodes within six months, reflects a state of chronic synovial vulnerability. Each episode of hemarthrosis contributes to iron deposition, synovial hypertrophy, and inflammatory activation, perpetuating a self-sustaining cycle of bleeding and joint damage. Importantly, even subclinical or unrecognized bleeds can initiate this cascade, emphasizing that joint deterioration may occur despite apparently low bleeding frequency [34].

3. Impact of Inhibitors on Musculoskeletal Deterioration

The presence of inhibitors is one of the most critical modifiers of disease severity and a major determinant of poor musculoskeletal outcomes. Inhibitors neutralize infused clotting factors, resulting in inadequate hemostatic control and increased frequency of bleeding episodes. Consequently, children with inhibitors experience prolonged and recurrent hemarthroses, which significantly accelerate synovial inflammation and osteochondral destruction.

Furthermore, the immune response associated with inhibitor development may contribute to a pro-inflammatory intra-articular environment, amplifying synovial proliferation and angiogenesis. Clinically, this translates into earlier onset of target joints, more rapid progression to chronic arthropathy, and greater functional impairment compared to inhibitor-negative patients [35].

4. Timing and Adequacy of Prophylaxis

Early initiation of prophylactic therapy is the cornerstone of preventing hemophilic arthropathy. Primary prophylaxis, initiated before the onset of joint bleeding (typically before age 2–3 years), has been shown

to significantly reduce bleeding frequency and preserve joint integrity. In contrast, delayed or suboptimal prophylaxis allows recurrent hemarthroses to occur during critical periods of joint development, resulting in irreversible structural damage.

Recent evidence suggests that maintaining higher trough levels of clotting factor (≥3–5%) may provide superior joint protection compared to the historically accepted threshold of 1%. However, achieving these targets remains challenging in many settings due to limited access to factor concentrates and variability in treatment adherence [36].

5. Genetic Susceptibility and Inflammatory Modifiers

Beyond the primary coagulation defect, genetic factors play a significant role in modulating susceptibility to joint damage. Polymorphisms associated with increased expression of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-α), have been linked to more severe arthropathy. Additionally, variations in genes involved in innate immune pathways, angiogenesis, and cartilage metabolism may influence the rate of joint deterioration.

These findings suggest that hemophilic arthropathy is not solely a mechanical consequence of bleeding but also involves genetically mediated inflammatory responses that determine disease severity and progression [37].

6. Environmental and Lifestyle Factors

Environmental influences, including physical activity, access to healthcare, and treatment adherence, significantly impact musculoskeletal outcomes. While high-impact activities may increase the risk of joint bleeding, structured physical activity and physiotherapy are essential for maintaining muscle strength, joint stability, and overall function. Early rehabilitation following hemarthrosis is particularly important in preventing contractures and long-term disability.

In addition, disparities in healthcare access, particularly in low-resource settings, contribute to delayed diagnosis, inadequate prophylaxis, and higher rates of arthropathy. These factors underscore the importance of comprehensive care models in improving outcomes [38].

7. Body Mass Index and Mechanical Stress

Increased body mass index (BMI) is an important and often underrecognized risk factor for joint deterioration. Excess weight places additional mechanical stress on weight-bearing joints, particularly the knees and ankles, exacerbating joint damage and accelerating degenerative changes. Obesity is also associated with reduced physical activity and impaired muscle support, further contributing to joint instability and bleeding risk.

Conversely, maintaining a healthy BMI and promoting appropriate physical conditioning can significantly improve joint outcomes and reduce disease burden in pediatric patients [39].

8. Treatment-Related Factors and Emerging Therapies

Treatment-related variables, including type of factor product, dosing regimen, and adherence, play a crucial role in determining musculoskeletal outcomes. The development of inhibitors, as well as variability in response to bypassing agents, can significantly compromise treatment efficacy. Emerging therapies, such as non-factor agents like emicizumab, offer more consistent hemostatic control and have shown promise in reducing bleeding rates, particularly in patients with inhibitors.

However, long-term data on their impact on joint health and disease progression in children remain limited, highlighting the need for ongoing research and longitudinal studies [40].

Summary Insight

The progression of hemophilic arthropathy in children is multifactorial, involving a dynamic interaction between biological, clinical, and environmental determinants. Among these, **inhibitors represent a pivotal factor that amplifies disease severity and accelerates joint damage**. A comprehensive

understanding of these risk factors is essential for early risk stratification, individualized management, and the development of targeted interventions aimed at preserving musculoskeletal health [41].

Assessment of Musculoskeletal Involvement in Pediatric Hemophilia

Accurate assessment of musculoskeletal status in children with hemophilia is essential for early detection of joint disease, monitoring progression, and guiding therapeutic interventions. Hemophilic arthropathy often begins with subtle or subclinical changes that may not be clinically apparent until significant structural damage has occurred. Therefore, a comprehensive evaluation strategy integrating clinical examination, imaging modalities, functional assessment tools, and emerging biomarkers is critical to capture the full spectrum of joint involvement and optimize patient outcomes [42].

Clinical assessment remains the cornerstone of musculoskeletal evaluation and is typically performed by experienced hematologists and physiotherapists. It involves systematic examination of joint swelling, pain, range of motion, muscle strength, and functional performance. Several standardized scoring systems have been developed to quantify joint health, among which the Hemophilia Joint Health Score (HJHS version 2.1) is the most widely validated and utilized, particularly in pediatric populations. The HJHS evaluates multiple domains including swelling, muscle atrophy, crepitus, joint pain, strength, and gait, providing a comprehensive measure of joint status. Lower scores indicate better joint health, and the tool has demonstrated excellent inter-observer reliability and sensitivity in detecting early joint changes [43].

Despite its utility, clinical examination alone may underestimate early or subclinical joint damage, particularly in children receiving prophylaxis who may not exhibit overt bleeding episodes. This limitation has driven the increasing use of imaging modalities to complement clinical assessment. Conventional radiography, although historically used, is limited in detecting early-stage arthropathy, as it primarily identifies late structural changes such as joint space narrowing, subchondral cysts, and bone deformities. The Pettersson scoring system remains a standard method for grading radiographic severity; however, its sensitivity to early disease is poor [44].

Magnetic resonance imaging (MRI) is considered the gold standard for detecting early joint changes in hemophilia. It allows detailed visualization of soft tissue structures, including synovial hypertrophy, cartilage integrity, and early osteochondral damage. MRI-based scoring systems, such as the Denver score and those developed by the International Prophylaxis Study Group, enable comprehensive evaluation of disease severity. However, the use of MRI in pediatric populations is limited by cost, accessibility, and the frequent need for sedation, making it less practical for routine or repeated assessments [45].

Musculoskeletal ultrasonography has emerged as a valuable, non-invasive, and accessible tool for joint assessment in hemophilia. It offers real-time visualization of synovial hypertrophy, joint effusion, and early structural changes without the need for radiation or sedation. The Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol provides a standardized scoring system that evaluates both disease activity and structural damage. Ultrasound has demonstrated good correlation with MRI findings and is particularly useful in point-of-care settings for detecting acute hemarthrosis and monitoring disease progression [46].

Functional assessment is an essential component of musculoskeletal evaluation, as it reflects the real-life impact of joint disease on daily activities and participation. Tools such as the Functional Independence Score in Hemophilia (FISH), the Hemophilia Activities List (HAL), and pediatric adaptations of these instruments provide valuable insights into patient mobility, self-care, and overall functional capacity. These assessments align with the World Health Organization's International Classification of Functioning, Disability and Health (ICF) framework, ensuring a holistic evaluation of disease burden beyond structural joint damage [47].

In addition to clinical and imaging tools, there is growing interest in the use of biomarkers to assess joint health and predict disease progression. Biomarkers related to cartilage degradation (such as CTX-II and COMP), bone turnover, and angiogenesis (such as VEGF) have shown potential in reflecting underlying pathological processes. However, their clinical application remains limited due to variability, lack of

specificity, and insufficient validation in large pediatric cohorts. As such, biomarkers are currently considered adjunctive tools rather than primary assessment methods [48].

The presence of inhibitors further complicates the assessment of musculoskeletal status. Inhibitor-positive patients often exhibit more rapid progression of joint damage, necessitating more frequent and detailed evaluations. Additionally, variability in bleeding patterns and treatment responses may obscure the relationship between clinical findings and underlying joint pathology. This highlights the importance of integrating multiple assessment modalities to achieve an accurate and comprehensive evaluation in this high-risk group [49].

Overall, the assessment of musculoskeletal involvement in pediatric hemophilia requires a multidimensional approach that combines clinical expertise with advanced diagnostic tools. Early detection of joint changes, particularly in children with inhibitors, is crucial for implementing timely interventions and preventing irreversible damage. Continued refinement of assessment methods and integration of novel technologies will further enhance the ability to monitor disease progression and improve long-term outcomes in this population [50].

Prevention and Management of Hemophilic Arthropathy in Children

Prevention of hemophilic arthropathy remains the cornerstone of modern hemophilia care, particularly in pediatric populations where early intervention can significantly alter long-term outcomes. The primary goal is to prevent joint bleeding and thereby interrupt the cascade leading to synovitis, cartilage damage, and irreversible joint destruction. Among all strategies, early initiation of prophylactic therapy has consistently demonstrated the greatest impact on preserving joint health and maintaining functional independence [51].

Prophylaxis involves the regular administration of clotting factor concentrates to maintain circulating factor levels sufficient to prevent spontaneous bleeding. Current recommendations emphasize the initiation of primary prophylaxis before the onset of joint disease, typically before the age of 2–3 years or prior to the second joint bleed. Evidence has shown that early prophylaxis significantly reduces bleeding frequency and prevents the development of target joints. Moreover, maintaining higher trough levels (≥3–5%) has been associated with improved joint protection compared to traditional lower thresholds [52].

Different prophylactic regimens have been described, including primary, secondary, and tertiary prophylaxis. Primary prophylaxis is initiated before joint damage occurs, while secondary prophylaxis begins after initial bleeding episodes but before established arthropathy. Tertiary prophylaxis is implemented after joint disease has already developed, aiming to prevent further progression. Although all forms provide benefit, early initiation yields the most favorable outcomes in terms of joint preservation and physical function [53].

In patients with inhibitors, prevention and management strategies become significantly more complex. Standard factor replacement therapy is ineffective, necessitating the use of bypassing agents such as activated prothrombin complex concentrates or recombinant activated factor VII. While these agents can control acute bleeding, their efficacy is variable and less predictable, which may result in ongoing subclinical bleeding and progressive joint damage. This highlights the need for optimized treatment protocols and close monitoring in this high-risk population [54].

Immune tolerance induction (ITI) represents the only established strategy for eradicating inhibitors and restoring responsiveness to factor replacement therapy. ITI involves the regular administration of high doses of clotting factor over an extended period, with success rates ranging from 70% to 90% in hemophilia A. However, the process is resource-intensive, requires long-term commitment, and is not universally successful. During ITI, patients remain vulnerable to bleeding episodes, which may further compromise joint health [55].

The advent of non-factor therapies, particularly emicizumab, has transformed the prophylactic landscape for patients with hemophilia A, including those with inhibitors. Emicizumab is a bispecific monoclonal antibody that mimics the function of factor VIII, providing more stable hemostatic control through subcutaneous administration. Clinical trials have demonstrated a significant reduction in bleeding rates

and improved patient adherence due to its convenient dosing schedule. Early evidence suggests that such therapies may play a critical role in preserving joint health, although long-term musculoskeletal outcomes in children require further evaluation [56].

Supportive management strategies are equally important in the prevention and treatment of hemophilic arthropathy. The RICE protocol (rest, ice, compression, elevation) remains a fundamental approach in the acute management of hemarthrosis, aiming to reduce bleeding, pain, and inflammation. In addition, physiotherapy plays a vital role in maintaining joint mobility, strengthening periarticular muscles, and preventing contractures. Early rehabilitation following bleeding episodes is essential to restore function and minimize long-term disability [57].

Pharmacological management of pain and inflammation must be carefully tailored in hemophilia patients. Selective cyclooxygenase-2 inhibitors are preferred for pain control due to their lower impact on platelet function compared to traditional nonsteroidal anti-inflammatory drugs. Adjunctive therapies such as desmopressin may be useful in selected patients with mild hemophilia A, enhancing endogenous factor VIII release and improving hemostasis in specific clinical scenarios [58].

Lifestyle modifications and patient education are critical components of comprehensive care. Encouraging safe physical activity, maintaining a healthy body weight, and promoting adherence to prophylactic regimens can significantly reduce bleeding risk and improve joint outcomes. Multidisciplinary care involving hematologists, physiotherapists, orthopedic specialists, and psychosocial support teams is essential to address the complex needs of pediatric patients and optimize long-term quality of life [59].

In summary, the prevention and management of hemophilic arthropathy in children require an integrated approach that combines early prophylaxis, effective management of inhibitors, advanced therapeutic options, and supportive care strategies. Particular attention must be given to children with inhibitors, as they represent a high-risk group for rapid disease progression. Ongoing advancements in therapy offer promising opportunities to further improve musculoskeletal outcomes and transform the natural history of hemophilia [60].

Impact of Hemophilic Arthropathy on Functional Outcomes and Quality of Life in Children

Hemophilic arthropathy has profound consequences on functional status and overall quality of life in pediatric patients, extending beyond structural joint damage to affect physical, psychological, and social domains. As joint disease progresses, children experience increasing limitations in mobility, participation in daily activities, and independence. These functional impairments often begin early in life and may persist into adulthood, highlighting the long-term burden of musculoskeletal complications in hemophilia [61].

One of the earliest functional consequences of joint involvement is a reduction in range of motion, which can be detected even in children with relatively few clinically apparent bleeding episodes. Progressive joint stiffness, muscle weakness, and pain contribute to impaired gait and reduced physical performance. In severe cases, joint deformities such as flexion contractures and limb length discrepancies may develop, further limiting mobility and increasing energy expenditure during movement. These changes can significantly interfere with normal growth and physical development [62].

Muscle atrophy is a common and often underappreciated consequence of chronic joint disease. Recurrent bleeding and pain lead to reduced use of affected limbs, resulting in muscle wasting and decreased strength. This, in turn, compromises joint stability and increases the risk of further bleeding, creating a vicious cycle of deterioration. In pediatric patients, muscle weakness can have lasting effects on motor development and coordination, potentially delaying milestones and limiting participation in physical activities [63].

Pain is a central determinant of functional limitation and quality of life in children with hemophilic arthropathy. Acute pain associated with bleeding episodes is often severe and requires prompt management, while chronic pain resulting from established joint damage can persist even in the absence of active bleeding. Chronic pain may lead to avoidance of movement, reduced physical activity, and decreased engagement in school and recreational activities. Over time, this can contribute to physical

deconditioning and further functional decline [64].

The psychosocial impact of hemophilic arthropathy is particularly significant in children and adolescents. Limitations in physical activity and participation may lead to social isolation, reduced self-esteem, and emotional distress. Children with visible joint deformities or functional impairments may experience stigma or difficulty integrating with peers. Additionally, the chronic nature of the disease and the need for ongoing treatment can place a psychological burden on both patients and their families [65].

Quality of life assessments in pediatric hemophilia have consistently demonstrated a strong correlation between joint health and overall well-being. Increased frequency of joint bleeding and greater severity of arthropathy are associated with poorer health-related quality of life scores. Tools such as the Haemophilia Activities List (HAL), Pediatric HAL, and Functional Independence Score in Hemophilia (FISH) provide valuable insights into the functional limitations experienced by patients and help guide individualized care plans [66].

The presence of inhibitors further exacerbates the impact on functional outcomes and quality of life. Children with inhibitors often experience more frequent and severe bleeding episodes, leading to earlier and more extensive joint damage. This results in greater functional impairment, increased pain, and higher treatment burden. Additionally, the complexity of managing inhibitors, including frequent hospital visits and invasive procedures, can further disrupt daily life and contribute to psychological stress [67].

Educational and occupational implications should also be considered, as chronic joint disease may affect school attendance, academic performance, and future career opportunities. Frequent medical appointments and physical limitations can interfere with regular schooling, while long-term disability may influence vocational choices. Early intervention and supportive measures are essential to minimize these impacts and promote optimal development [68].

Overall, hemophilic arthropathy significantly compromises functional outcomes and quality of life in pediatric patients, with effects that extend across multiple domains of health and development. The burden is particularly pronounced in children with inhibitors, who are at increased risk of rapid disease progression and disability. A comprehensive, multidisciplinary approach that addresses both physical and psychosocial aspects is essential to improve long-term outcomes and ensure holistic care for this vulnerable population [69].

Conclusion

Hemophilic arthropathy remains a major determinant of morbidity in children with hemophilia, arising from a complex interplay between recurrent joint bleeding, chronic synovial inflammation, and progressive osteochondral damage. Despite advances in prophylactic therapies, joint disease continues to develop, particularly in patients with severe disease and those complicated by inhibitor formation. Inhibitors represent a critical modifier that not only compromises hemostatic control but also accelerates musculoskeletal deterioration, leading to earlier onset of joint damage, increased functional impairment, and reduced quality of life. Early identification of high-risk patients and timely intervention are therefore essential to interrupt the cycle of bleeding and joint destruction.

A comprehensive, multidisciplinary approach integrating early prophylaxis, optimized inhibitor management, advanced imaging, and functional assessment is fundamental to preserving joint health in pediatric patients. Emerging therapies, including non-factor agents, offer promising opportunities to improve bleeding control and potentially alter disease trajectory, especially in inhibitor-positive populations. However, continued research is needed to better understand long-term musculoskeletal outcomes and refine individualized treatment strategies. Ultimately, improving awareness, early detection, and targeted management will be key to minimizing disability and enhancing lifelong outcomes for children with hemophilia.

References

1. Mannucci PM, Tuddenham EGD. The hemophilias—from royal genes to gene therapy. *N Engl J Med*. 2001;344(23):1773-1779.
2. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. *Lancet*. 2003;361(9371):1801-1809.
3. Monroe DM, Hoffman M. What does it take to make the perfect clot? *Arterioscler Thromb Vasc Biol*. 2006;26(1):41-48.
4. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. *Lancet*. 2016;388:187-197.
5. Oldenburg J. Mutation profiling in haemophilia A. *Thromb Haemost*. 2001;85(4):577-579.
6. Lalezari S, Barg AA, Dardik R, et al. Women with hemophilia: case series of reproductive choices and review of literature. *TH Open*. 2021;5(2):e183-e187.
7. Lan HH, Eustace SJ, Dorfman D. Hemophilic arthropathy. *Radiol Clin North Am*. 1996;34:446-450.
8. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. *J Comorb*. 2011;1:51.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med*. 2007;357(6):535-544.
10. Soucie JM, Wang C, Forsyth A, et al. Range of motion limitations among young males with hemophilia: prevalence and risk factors. *Blood*. 2004;103/104:2467-2473.
11. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. *J Thromb Haemost*. 2010;8(9):1895-1902.
12. Acharya SS, Kaplan RN, Macdonald D, Fabiyi OT, DiMichele D, Lyden D. Neoangiogenesis contributes to the development of hemophilic synovitis. *Blood*. 2011;117:2484-2493.
13. Blobel CP, Haxaire C, Kalliolias GD, DiCarlo E, Salmon J, Srivastava A. Blood-induced arthropathy in hemophilia: mechanisms and heterogeneity. *Semin Thromb Hemost*. 2015;41:832-837.
14. Pulles AE, Mastbergen SC, Schutgens REG, Lafeber FPJG, van Vulpen LFD. Pathophysiology of hemophilic arthropathy and potential targets for therapy. *Pharmacol Res*. 2017;115:192-199.
15. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. *J Thromb Haemost*. 2021;19(9):2112-2121.
16. Cooke EJ, Zhou JY, Wyseure T, et al. Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice. *Thromb Haemost*. 2018;118:1036-1047.
17. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. *Ann Rheum Dis*. 2000;59:945-953.
18. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. *Blood*. 2004;104:2060-2064.
19. Melchiorre D, Milia AF, Linari S, et al. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology. *J Rheumatol*. 2012;39:1678-1686.
20. Jiang J, Leong NL, Khalique U, Phan TM, Lyons KM, Luck JV Jr. Connective tissue growth factor (CTGF/CCN2) in haemophilic arthropathy and arthrofibrosis: a histological analysis. *Haemophilia*. 2016;22:e527-e536.
21. Beyer R, Ingerslev J, Sørensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. *Haemophilia*. 2010;16(6):926-931.
22. Abdel-Messih IY, Mohamed Habashy DM, Moftah SG, El-Alfy M. Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A. *Haemophilia*. 2011;17:490-493.
23. Donfield SM, Lynn HS, Lail AE, Hoots WK, Berntorp E, Gomperts ED. Delays in maturation among adolescents with hemophilia and a history of inhibitors. *Blood*. 2007;110:3656-3661.
24. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. *Blood*. 2007;109(11):4648-4654.
25. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. *Haemophilia*. 2010;16(suppl 2):10-15.
26. Kempton CL, White GC II. How we treat a hemophilia A patient with a factor VIII inhibitor. *Blood*. 2009;113(1):11-17.
27. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency: a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). *Haemophilia*. 2009;15(5):1027-1031.

28. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. *Blood*. 2012;119:1335-1344.
29. Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder. *Haemophilia*. 2010;16:2-3.
30. Hart DP, Alamelu J, Bhatnagar N, et al. Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update. *Haemophilia*. 2021;27:932-937.
31. Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. *Eur J Haematol*. 2019;102:111-122.
32. Ragni MV, George LA. The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science workshop on factor VIII inhibitors. *Haemophilia*. 2019;25:581-589.
33. Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. *Haematologica*. 2021;106:123-129.
34. Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, DiMichele D, et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. *Haemophilia*. 2006;12(suppl 6):1-7.
35. Di Minno MN, Di Minno G, Di Capua M, et al. Cost of care of haemophilia with inhibitors. *Haemophilia*. 2010;16:e190-e201.
36. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. *Haemophilia*. 2020;26(suppl 6):1-158.
37. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. *Haemophilia*. 2013;19:e1-e47.
38. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. *J Thromb Haemost*. 2009;7:413-420.
39. Den Uijl IEM, Fischer K, van der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low-frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. *Haemophilia*. 2011;17:41-44.
40. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. *Blood*. 2015;125:2038-2044.
41. Manco-Johnson MJ, Soucie JM, Gill JC, et al. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. *Blood*. 2017;129:2368-2374.
42. Gooding R, Thachil J, Alamelu J, Motwani J, Chowdary P. Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers. *J Blood Med*. 2021;12:209-220.
43. Gomperts ED, Schwarz J, Donfield SM, et al. The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A. *Thromb Haemost*. 2017;117:277-285.
44. Barnes C, Wong P, Egan B, et al. Reduced bone density among children with severe hemophilia. *Pediatrics*. 2004;114:177-181.
45. Iorio A, Fabbriciani G, Marcucci M, Brozzetti M, Filipponi P. Bone mineral density in haemophilia patients: a meta-analysis. *Thromb Haemost*. 2010;103(3):596-603.
46. Anagnostis P, Karras S, Paschou SA, et al. Haemophilia A and B as a cause for secondary osteoporosis and increased fracture risk. *Blood Coagul Fibrinolysis*. 2015;26(6):599-603.
47. Shapiro AD. Hemophilic arthropathy: current concepts in pathogenesis and management. *Blood Rev*. 2019.
48. Feldman BM, Funk S, Zourikian N, et al. The Hemophilia Joint Health Score version 2.1: validation and reliability. *Haemophilia*. 2011;17:273-281.
49. Hilliard P, Funk S, Zourikian N, et al. Hemophilia Joint Health Score reliability study. *Haemophilia*. 2006;12(5):518-525.
50. Gilbert MS. Prophylaxis: musculoskeletal evaluation. *Semin Hematol*. 1993;30:3-6.
51. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. *Clin Orthop Relat Res*. 1980;149:153-159.
52. Doria AS, Lundin B, Kilcoyne RF, et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI working group of the International Prophylaxis Study Group. *Haemophilia*. 2005;11:245-253.
53. Lundin B, Berntorp E, Pettersson H, et al. Gadolinium contrast agent is of limited value for magnetic resonance imaging assessment of synovial hypertrophy in hemophiliacs. *Acta Radiol*. 2007;48(5):520-530.
54. Ceponis A, Wong-Sefidan I, Glass CS, von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult

haemophilia patients. *Haemophilia*. 2013;19:790-798.

55. Di Minno MND, Iervolino S, Soscia E, et al. Magnetic resonance imaging and ultrasound evaluation of "healthy" joints in young subjects with severe haemophilia A. *Haemophilia*. 2013;19:e167-e173.
56. Doria AS, Keshava SN, Mohanta A, et al. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. *AJR Am J Roentgenol*. 2015;204:W336-W347.
57. Martinoli C, Della Casa Alberighi O, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for haemophilia early arthropathy detection with ultrasound (HEAD-US). *Thromb Haemost*. 2013;109:1170-1179.
58. Foppen W, van der Schaaf IC, Fischer K, et al. Value of routine ultrasound in detecting early joint changes in children with haemophilia using the HEAD-US protocol. *Haemophilia*. 2016;22:121-125.
59. Foppen W, van der Schaaf IC, Beek FJA, Mali W, Fischer K. Diagnostic accuracy of point-of-care ultrasound for evaluation of early blood-induced joint changes: comparison with MRI. *Haemophilia*. 2018;24(6):971-979.
60. Ligocki CC, Abadeh A, Wang KC, Adams-Webber T, Blanchette VS, Doria AS. A systematic review of ultrasound imaging as a tool for evaluating haemophilic arthropathy in children and adults. *Haemophilia*. 2017;23(4):598-612.
61. Ignas DM, Doria AS, von Drygalski A, et al. Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: results of an International Prophylaxis Study Group global survey. *Haemophilia*. 2020;26:685-693.
62. Bakeer N, Shapiro AD. Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia. *F1000Res*. 2019;8:10.
63. Manon-Jensen T, Tangada S, Bager C, et al. Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial. *J Thromb Haemost*. 2024;22(1):90-100.
64. van Bergen EDP, Fischer K, et al. Biomarker research in haemophilic arthropathy remains exploratory and heterogeneous. *Haemophilia*. 2021.
65. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies. *Blood*. 2021;137(16):2231-2242.
66. Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. *Haemophilia*. 2022;28(6):1033-1043.
67. Okaygoun D, Oliveira DD, Soman S, Williams R, et al. Advances in the management of haemophilia: emerging treatments and their mechanisms. *J Biomed Sci*. 2021;28:64.
68. Bhardwaj R, Rath G, Goyal AK, et al. Advancement in the treatment of haemophilia. *Int J Biol Macromol*. 2018;118:289-295.